Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial - Hueber, W; Sands, B E; Lewitzky, S (Gut, 2012)
doi: 10.1136/gutjnl-2011-301668